CN Patent

CN115666565A — 用于治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂

Assigned to Aragon Pharmaceuticals Inc · Expires 2023-01-31 · 3y expired

What this patent protects

本文描述了用雄激素受体抑制剂治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的方法，该雄激素受体抑制剂包括但不限于4‑[7‑(6‑氰基‑5‑三氟甲基吡啶‑3‑基)‑8‑氧代‑6‑硫代‑5,7‑二氮杂螺[3.4]辛‑5‑基]‑2‑氟‑N‑甲基苯甲酰胺。

USPTO Abstract

本文描述了用雄激素受体抑制剂治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的方法，该雄激素受体抑制剂包括但不限于4‑[7‑(6‑氰基‑5‑三氟甲基吡啶‑3‑基)‑8‑氧代‑6‑硫代‑5,7‑二氮杂螺[3.4]辛‑5‑基]‑2‑氟‑N‑甲基苯甲酰胺。

Drugs covered by this patent

Patent Metadata

Patent number
CN115666565A
Jurisdiction
CN
Classification
—
Expires
2023-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Aragon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.